Candid Therapeutics recorded San Diego’s largest venture capital deal during the third quarter. It was also the fourth largest deal in California.

Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and increased the price target ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is ...

Fintel reports that on October 16, 2024, Raymond James upgraded their outlook for Wave Life Sciences (NasdaqGM:WVE) from ...

This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases. Its stock surged as ...

While RNA-medicine developer Wave Life Sciences Ltd. brought in a clinical data win, it also got knocked back a step as a major collaborator will go its separate way. That didn’t stop Wave’s stock ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

Wave Life Sciences is a clinical-stage biotechnology company based in Cambridge, MA, dedicated to unlocking the potential of RNA medicines to transform human health. With a robust pipeline focused on ...

Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of ...

In terms of liquidity and interest, the mean open interest for WAVE Life Sciences options trades today is 608.71 with a total ...